Acromegaly
📧 Sign up to get email alerts when something new happens for Acromegaly.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2014-12-08Clinical Trial Update: Epidemiology of Acromegaly in Denmark 1991-2010
This clinical trial update reports on the epidemiology of acromegaly in Denmark from 1991 to 2010.
-
CLINICAL_TRIALS trial_result · 2014-12-05Clinical Trial Update: Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors
This completed clinical trial evaluated calcium homeostasis in acromegaly and how surgical or medical treatment affects it. It also compared…
-
FDA approval · 2014-11-26FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for bromocriptine mesylate submitted by ANI Pharmaceuticals, Inc. This action updates the regula…
-
FDA approval · 2014-10-28FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) from Ipsen Biopharmaceuticals, Inc., expanding its app…
-
CLINICAL_TRIALS trial_result · 2014-10-28Clinical Trial Update: Fractionated Stereotactic Radiotherapy in Patients With Acromegaly
A completed clinical trial evaluating fractionated stereotactic radiotherapy for acromegaly.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-09-16Clinical Trial Update: Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance
A completed clinical trial examining how growth hormone excess in acromegaly influences glucose tolerance, insulin resistance, and glucose m…
-
FDA approval · 2014-07-31FDA Approved: SOMAVERT — Supplemental Application (Pharmacia & Upjohn Company LLC)
The FDA approved a supplemental application for SOMAVERT (pegvisomant) from Pharmacia & Upjohn Company LLC.
-
CLINICAL_TRIALS trial_result · 2014-07-31Clinical Trial Update: Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone [NA]
A completed trial evaluated preoperative somatostatin analogue therapy for acromegaly and compared it with neurosurgery alone before pituita…
-
CLINICAL_TRIALS trial_result · 2014-06-02Clinical Trial Update: Preoperative Octreotide Treatment of Acromegaly [Phase 4]
This update notes the completion of a Phase 4 clinical trial evaluating preoperative octreotide treatment in patients with acromegaly.
-
FDA approval · 2014-05-19FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) from Novartis, resulting in an updated labeling to re…
-
FDA approval · 2014-01-30FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) submitted by Novartis Pharmaceuticals Corporation. Th…
-
CLINICAL_TRIALS trial_result · 2013-12-23Clinical Trial Update: Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma [Phase 3]
Phase 3 trial evaluating lanreotide as the primary treatment for acromegaly due to pituitary macroadenoma.
-
FDA approval · 2013-12-10FDA Approved: SOMAVERT — Supplemental Application (Pharmacia & Upjohn Company LLC)
The FDA approves a supplemental application for Somavert (pegvisomant) from Pharmacia & Upjohn Company LLC.
-
FDA approval · 2013-11-12FDA Approved: OCTREOTIDE ACETATE — Original Application (Sagent Pharmaceuticals)
FDA approved Sagent Pharmaceuticals' generic octreotide acetate (OCTREOTIDE ACETATE) through an Original Application (ANDA).
-
FDA approval · 2013-11-12FDA Approved: OCTREOTIDE ACETATE — Original Application (Sagent Pharmaceuticals)
FDA approved Sagent Pharmaceuticals' Original Application for octreotide acetate injectable, a generic form of octreotide. It is approved fo…
-
FDA approval · 2013-10-11FDA Approved: SOMAVERT — Supplemental Application (Pharmacia & Upjohn Company LLC)
The FDA approved a supplemental application for Somavert (pegvisomant) filed by Pharmacia & Upjohn Company LLC.
-
CLINICAL_TRIALS trial_result · 2013-09-27Clinical Trial Update: Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly [Phase 3]
A Phase 3 trial evaluating an octreotide implant for acromegaly was terminated.
-
FDA approval · 2013-09-26FDA Approved: SOMAVERT — Supplemental Application (Pharmacia & Upjohn Company LLC)
The FDA approved a supplemental application for SOMAVERT (pegvisomant) submitted by Pharmacia & Upjohn Company LLC.
-
CLINICAL_TRIALS research · 2013-09-26Clinical Trial Update: The Observational Study of Growth Hormone-secreting Pituitary Tumors
This entry reports an observational study investigating growth hormone-secreting pituitary tumors, including acromegaly and pituitary adenom…
-
CLINICAL_TRIALS other · 2013-09-20Clinical Trial Update: Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly [Phase 3]
A Phase 3 long-term safety and efficacy study of an octreotide implant for acromegaly has been terminated.
-
FDA approval · 2013-07-31FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' supplemental application for Bromocriptine Mesylate, resulting in updated labeling for the product.
-
CLINICAL_TRIALS research · 2013-07-19Clinical Trial Update: Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly
This entry describes a clinical trial investigating AIP gene mutations in acromegaly; the trial status is currently unknown.
-
FDA label_change · 2013-06-12FDA Approved: CYCLOSET — Supplemental Application (Avvisto Therapeutics LLC)
The FDA approved a supplemental application for CYCLOSET (bromocriptine mesylate) submitted by Avvisto Therapeutics LLC. The action involves…
-
FDA approval · 2013-05-23FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for Octreotide acetate submitted by Mylan Institutional LLC.
-
FDA approval · 2013-03-14FDA Approved: CYCLOSET — Supplemental Application (Avvisto Therapeutics LLC)
FDA approved a supplemental application for CYCLOSET (bromocriptine mesylate) from Avvisto Therapeutics LLC.